Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.595 USD | -9.74% | -13.91% | -18.24% |
Mar. 07 | Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024 |
Financials (USD)
Sales 2024 * | 8.81M | Sales 2025 * | 8.64M | Capitalization | 23.33M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -39M | EV / Sales 2024 * | 2.65 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.7 x |
P/E ratio 2024 * |
-1.02
x | P/E ratio 2025 * |
-1.43
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.98% |
Latest transcript on Lumos Pharma, Inc.
1 day | -9.74% | ||
1 week | -13.91% | ||
Current month | -7.47% | ||
1 month | +6.12% | ||
3 months | -14.75% | ||
6 months | -17.20% | ||
Current year | -18.24% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 2.6 | -9.57% | 49 384 |
24-05-13 | 2.875 | -0.86% | 11,233 |
24-05-10 | 2.9 | -3.97% | 32,880 |
24-05-09 | 3.02 | +0.66% | 31,555 |
24-05-08 | 3 | -0.66% | 12,524 |
Delayed Quote Nasdaq, May 14, 2024 at 01:02 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.24% | 23.33M | |
+28.82% | 48.16B | |
-1.09% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.11% | 25.59B | |
-22.87% | 18.96B | |
+8.05% | 12.92B | |
+29.01% | 12.03B | |
-1.85% | 11.77B |
- Stock Market
- Equities
- LUMO Stock